Eyeing standard of care status in 3rd-line TNBC, Gilead nails down full OK for Trodelvy with a slightly broader label

Even as the FDA gets tough on drugs that miss their mark after accelerated approvals, the agency is still quick to reward the ones that hit it.

Gilead is touting one such case in Trodelvy, which clamped down a full OK just under one year after it was initially cleared...

Click to view original post